Medigen Vaccine Biologics Corporation (TPEX: 6547)
Taiwan
· Delayed Price · Currency is TWD 37.70
+0.60 (1.62%)
Nov 19, 2024, 1:30 PM CST
Medigen Vaccine Biologics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 648.17 | 389.62 | 365.04 | 3,281 | 11.51 | 1.12 | Upgrade
|
| Revenue Growth (YoY) | 167.82% | 6.73% | -88.87% | 28413.03% | 927.41% | - | Upgrade
|
| Cost of Revenue | 204.67 | 159.4 | 577.64 | 975.96 | 3.87 | - | Upgrade
|
| Gross Profit | 443.5 | 230.22 | -212.6 | 2,305 | 7.64 | 1.12 | Upgrade
|
| Selling, General & Admin | 332.75 | 243.44 | 183.67 | 148.21 | 91.96 | 66.3 | Upgrade
|
| Research & Development | 757.3 | 1,201 | 1,140 | 1,193 | 679.56 | 538.73 | Upgrade
|
| Operating Expenses | 1,090 | 1,444 | 1,324 | 1,341 | 771.52 | 605.03 | Upgrade
|
| Operating Income | -646.54 | -1,214 | -1,536 | 963.73 | -763.88 | -603.91 | Upgrade
|
| Interest Expense | -26.19 | -37.57 | -26.89 | -6.02 | -16.42 | -19.13 | Upgrade
|
| Interest & Investment Income | 53.11 | 83.28 | 7.61 | 2.74 | 1.48 | 4.71 | Upgrade
|
| Currency Exchange Gain (Loss) | -35.78 | -0.33 | 28.86 | 7.52 | 4.15 | 0.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 14.91 | 8.61 | 32.25 | -0.07 | 0.19 | - | Upgrade
|
| EBT Excluding Unusual Items | -640.49 | -1,160 | -1,494 | 967.9 | -774.49 | -617.96 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.06 | 0.24 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 19.73 | - | Upgrade
|
| Other Unusual Items | - | - | 19.86 | 442.36 | 80.54 | - | Upgrade
|
| Pretax Income | -640.49 | -1,160 | -1,475 | 1,410 | -674.28 | -617.72 | Upgrade
|
| Net Income | -640.49 | -1,160 | -1,475 | 1,410 | -674.28 | -617.72 | Upgrade
|
| Net Income to Common | -640.49 | -1,160 | -1,475 | 1,410 | -674.28 | -617.72 | Upgrade
|
| Shares Outstanding (Basic) | 325 | 328 | 323 | 319 | 277 | 231 | Upgrade
|
| Shares Outstanding (Diluted) | 325 | 328 | 323 | 321 | 277 | 231 | Upgrade
|
| Shares Change (YoY) | -0.81% | 1.50% | 0.73% | 15.82% | 20.08% | 3.64% | Upgrade
|
| EPS (Basic) | -1.97 | -3.53 | -4.56 | 4.42 | -2.43 | -2.68 | Upgrade
|
| EPS (Diluted) | -1.97 | -3.53 | -4.56 | 4.39 | -2.43 | -2.68 | Upgrade
|
| Free Cash Flow | -131.91 | -517.02 | -1,353 | 446.26 | -689.22 | -469.86 | Upgrade
|
| Free Cash Flow Per Share | -0.41 | -1.57 | -4.18 | 1.39 | -2.49 | -2.03 | Upgrade
|
| Gross Margin | 68.42% | 59.09% | -58.24% | 70.25% | 66.36% | 100.00% | Upgrade
|
| Operating Margin | -99.75% | -311.54% | -420.85% | 29.37% | -6638.40% | -53920.71% | Upgrade
|
| Profit Margin | -98.81% | -297.68% | -403.95% | 42.98% | -5859.74% | -55153.39% | Upgrade
|
| Free Cash Flow Margin | -20.35% | -132.70% | -370.64% | 13.60% | -5989.55% | -41951.34% | Upgrade
|
| EBITDA | -515.42 | -1,098 | -1,423 | 1,072 | -653.8 | -497.44 | Upgrade
|
| EBITDA Margin | -79.52% | -281.86% | - | 32.68% | - | - | Upgrade
|
| D&A For EBITDA | 131.12 | 115.64 | 112.91 | 108.34 | 110.08 | 106.47 | Upgrade
|
| EBIT | -646.54 | -1,214 | -1,536 | 963.73 | -763.88 | -603.91 | Upgrade
|
| EBIT Margin | -99.75% | - | - | 29.37% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.